- Pfizer Inc. (NYSE: PFE) today announced the publication of complete results from the JADE COMPARE study of investigational oral, once-daily, Janus kinase 1 (JAK1) inhibitor, abrocitinib in The New England Journal of Medicine (NEJM). The study evaluated the safety and efficacy of two doses of abrocitinib, 100mg and 200mg, versus placebo in adults with moderate to severe atopic dermatitis who were on background topical therapy. The study included an active control arm where patients were treated with dupilumab, a biologic treatment administered by subcutaneous injection. Both doses of abrocitinib met the co-primary study endpoints. The manuscript was published in the March 25, 2021 issue of NEJM.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
